Review of the molecular profile and modern prognostic markers for gastric lymphoma: How do they affect clinical practice?

Canadian Journal of Surgery

Volumn 55, Issue 2, 2012, Pages 117-124

  Alevizos, Leonidas ^a   Gomatos, Ilias P ^a   Smparounis, Spyridon ^a   Konstadoulakis, Manousos M ^a   Zografos, Georgios ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860674386     PISSN: 0008428X     EISSN: 14882310     Source Type: Journal    
DOI: 10.1503/cjs.002310     Document Type: Review

References (85)

1. Bailey RL, Laws HL. Lymphoma of the stomach. Am Surg 1989; 55:665-8. (Pubitemid 19284740)
2. Brands F, Monig SP, Raab M. Treatment and prognosis of gastric lymphoma. Eur J Surg 1997;163:803-13. (Pubitemid 27485955)
3. Isaacson PG, Spencer J. Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology 1987;11:445-62. (Pubitemid 17079432)
4. Azab MB, Henry-Amar M, Rougier P. Prognostic factors in primary gastrointestinal non-Hodgkin's lymphoma. A multivariate analysis, report of 106 cases, and review of the literature. Cancer 1989;64: 1208-17. (Pubitemid 19217096)
5. Musshoff K. Klinische Stadieneinteilung der Nicht-Hodgkin lymphome. [Article in German]. Strahlentherapie 1977;153:218-21.
6. Cogliatti SB, Schmid U, Schumacher U, et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology 1991;101:1159-70.
7. Talamonti MS, Dawes LG, Joehl RJ, et al. Gastrointestinal lymphoma: a case for primary surgical resection. Arch Surg 1990;125: 972-6.
8. Lim FE, Hartman AS, Tan EG, et al. Factors in the prognosis of gastric lymphoma. Cancer 1977;39:1715-20. (Pubitemid 8107727)
9. Rodenhuis S. ras and human tumors. Semin Cancer Biol 1992;3:241-7.
10. Cirisano FD, Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig 1996;3:99-105. (Pubitemid 26139457)
11. Hiyama T, Haruma K, Kitadai Y, et al. K-ras mutation in helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. Int J Cancer 2002;97:562-6. (Pubitemid 34087791)
12. Einspahr JG, Martinez ME, Ruiyun J, et al. Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics. Cancer Epidemiol Biomarkers Prev 2006;15:1443-50. (Pubitemid 44299313)
13. Catalano T, Curia MC, Aceto G, et al. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. Oncol Rep 2005;14:625-31.
14. Seiden-Long IM, Brown KR, Shih W, et al. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. Oncogene 2006;25:91-102. (Pubitemid 43050007)
15. Lin JK, Shih-Ching C, Huann-Sheng W, et al. Distinctive clinicopathological features of Ki-ras mutated colorectal cancers. J Surg Oncol 2006;94:234-41.
16. Bazan V, Bruno L, Augello C, et al. Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol 2006;17(Suppl 7):vii84-90. (Pubitemid 43985187)
17. Olson MF, Paterson HF, Marshall CJ. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 1998;394:295-9. (Pubitemid 28335044)
18. Fang JY, Zhu SS, Xiao SD, et al. Studies on the hypomethylation of c-myc, c-Ha-ras oncogenes and histopathological changes in human gastric carcinoma. J Gastroenterol Hepatol 1996;11:1079-82.
19. Li JW, Chuang TC, Yang AH, et al. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan. Int J Oncol 2005;26:933-43.
20. Zhang XL, Yang YS, Xu DP, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009; 33: 2112-8.
21. Ochs AM, Wong L, Kakani V, et al. Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Col Cancer 2004;4:262-7. (Pubitemid 40012323)
22. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68. (Pubitemid 32619394)
23. Ferreri AJ, Ponzoni M, Pruneri G, et al. Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. Int J Cancer 2001;94:599-604.
24. Min KO, Seo EJ, Kwon HJ, et al. Methylation of p16(INK4A) and p57(KIP2) are involved in the development and progression of gastric MALT lymphomas. Mod Pathol 2006;19:141-8.
25. Ricci R, Arena V, Castri F, et al. Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol 2004;122:35-43. (Pubitemid 38849870)
26. Schneider-Stock R, Boltze C, Lasota J, et al. High prognostic value of p16INK4 Alterations in gastrointestinal stromal tumors. J Clin Oncol 2003;21:1688-97. (Pubitemid 46638579)
27. Sarbia M, Geddert H, Klump B, et al. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF, and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer 2004;111:224-8. (Pubitemid 38924699)
28. Schmieder M, Wolf S, Danner B, et al. p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. Neoplasia 2008;10:1154-62.
29. Li AF, Li A, Tsay SH, et al. Alterations in the p16INK4a/Cyclin D1/RB pathway in gastrointestinal tract endocrine tumors. Am J Clin Pathol 2008;130:535-42.
30. Hong J, Resnick M, Behar J, et al. Acid-induced P16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. Am J Physiol Gastrointest Liver Physiol 2010;299:G697-706.
31. Ajani JA, Wang X, Izzo JG, et al. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci 2010;55:1098-105.
32. Yasui W, Oue N, Kuniyasu H, et al. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 2001;4:113-21. (Pubitemid 33123473)
33. Liu H, Ye H, Dogan A, et al. t(11,18)(q21,q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001;98:1182-7.
34. Fan YS, Rizkalla K, Engel J. Interstitial deletion of 8(q13q22) in diffuse large B-cell gastric lymphoma. Cancer Genet Cytogenet 1999;115:28-31. (Pubitemid 29505215)
35. Joensuu H, Soderstrom KO, Klemi PJ, et al. Nuclear DNA content and its prognostic value in lymphoma of the stomach. Cancer 1987; 60:3042-8. (Pubitemid 18005882)
36. Aydin ZD, Barista I, Canpinar H, et al. Gastric lymphomas in Turkey. Analysis of prognostic factors with special emphasis on flow cytometric DNA content. Cancer 2000;89:12-20. (Pubitemid 30451268)
37. Gisbertz IA, Schouten HC, Bot FJ, et al. Proliferation and apoptosis in primary gastric B-cell non-Hodgkin's lymphoma. Histopathology 1997;30:152-9. (Pubitemid 27101432)
38. Gisbertz IA, Schouten HC, Bot FJ. Cell turnover parameters in small and large cell varieties of primary intestinal non-Hodgkin's lymphoma. Cancer 1998;83:158-65. (Pubitemid 28299642)
39. Koda M, Reszec J, Sulkowska M, et al. Expression of the insulin-like growth factor-I receptor and proapoptotic Bax and Bak proteins in human colorectal cancer. Ann N Y Acad Sci 2004;1030:377-83. (Pubitemid 40378936)
40. Tahara M, Ochiai A, Fujimoto J, et al. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep 2004;11:9-15.
41. Gao C, Wang AY. Significance of increased apoptosis and Bax expression in human small intestinal adenocarcinoma. J Histochem Cytochem 2009;57:1139-48.
42. Nehls O, Hass HG, Okech T, et al. Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone. Int J Colorectal Dis 2009;24:655-63.
43. Aggarwal S, Taneja N, Lin L, et al. Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia 2000;2:346-56.
44. Nehls O, Okech T, Hsieh C-J, et al. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer 2007;96:1409-18. (Pubitemid 46685789)
45. Saadi A, Shannon NB, Lao-Sirieix P, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A 2010;107:2177-82.
46. Liang R, Chan WP, Kwong YL, et al. Bcl-6 gene hypermutations in diffuse large B-cell lymphoma of primary gastric origin. Br J Haematol 1997;99:668-70. (Pubitemid 27519872)
47. Charalambous GK, Gomatos IP, Konstadoulakis MM, et al. Protein expression of bax, bcl-2, and p53 in patients with non-Hodgkin's gastric lymphoma: prognostic significance. World J Surg 2000;24:608-14. (Pubitemid 30210854)
48. Isaacson PG. Gastric MALT lymphoma: from concept to cure. Ann Oncol 1999;10:637-45. (Pubitemid 29342367)
49. Liang R, Chan WP, Kwong YL, et al. High incidence of bcl-6 gene rearrangement in diffuse large B-cell lymphoma of primary gastric origin. Cancer Genet Cytogenet 1997;97:114-8. (Pubitemid 27362504)
50. Sadowski-Debbing K, Coy JF, Mier W, et al. Caspases: their role in apoptosis and other physiological processes as revealed by knock-out studies. Arch Immunol Ther Exp (Warsz) 2002;50:19-34.
51. Voutsadakis IA. Apoptosis and the pathogenesis of lymphoma. Acta Oncol 2000;39:151-6. (Pubitemid 30316881)
52. Takahashi A, Kono K, Amemiya H, et al. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer. Clin Cancer Res 2001;7:74-80. (Pubitemid 32110207)
53. Go JH, Yang WI. Expressions of p53 and p21 in primary gastric lymph omas. J Korean Med Sci 2001;16:731-5. (Pubitemid 33741059)
54. Tang DG, Honn KV. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis 1994-1995;14:109-22.
55. Roos E. Adhesion molecules in lymphoma metastasis. Cancer Metastasis Rev 1991;10:33-48.
56. Ke JJ, Shao QS, Ling ZQ. Expression of E-selectin, integrin β1 and immunoglobulin superfamily member in human gastric carcinoma cells and its clinicopathologic significance. World J Gastroenterol 2006; 12:3609-11.
57. Hayes SHH, Seigel GM. Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. Int J Clin Exp Pathol 2009;2: 553-60.
58. Vainer B, Horn T, Nielsen OH. Colonic epithelial cell expression of ICAM-1 relates to loss of surface continuity: a comparative study of inflammatory bowel disease and colonic neoplasms. Scand J Gastroenterol 2006;41:318-25.
59. Terol M-J, Lopez-Guillermo A, Bosch F, et al. Expression of the adhesion molecule icam-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. J Clin Oncol 1998;16:35-40. (Pubitemid 28041576)
60. Charpin C, Devictor B, Bergeret D, et al. CD31 quantitative immuno cytochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Pathol 1995;103:443-8.
61. Charpin C, Garcia S, Bouvier C, et al. CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas: correlation with patient follow-up. Am J Clin Pathol 1997;107:534-41. (Pubitemid 27183985)
62. Darom A, Gomatos IP, Leandros E, et al. Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients. World J Gastroenterol 2006;12:1924-32.
63. Liu YX, Yoshino T, Ohara N, et al. Loss of expression of alpha4beta7 integrin and L-selectin is associated with high-grade progression of low-grade MALT lymphoma. Mod Pathol 2001;14:798-805. (Pubitemid 33069839)
64. Sato Y, Ito M, Morise K, et al. Expression of adhesion molecules in primary B-cell gastric lymphoma and lymphoid follicles. Virchows Arch 1996;429:377-82. (Pubitemid 26421399)
65. Saito H, Tsujitani S. Angiogenesis, angiogenic factor expression and prognosis of gastric carcinoma. Anticancer Res 2001;21:4365-72. (Pubitemid 34240967)
66. Schaerer L, Schmid MH, Mueller B, et al. Angiogenesis in cutaneous lymphoproliferative disorders: microvessel density discriminates between cutaneous B-cell lymphomas and B-cell pseudolymphomas. Am J Dermatopathol 2000;22:140-3. (Pubitemid 30185836)
67. Konturek SJ, Konturek PC, Hartwich A, et al. Helicobacter pylori infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies. Regul Pept 2000;93:13-9.
68. Tsuji S, Tsujii M, Kawano S, et al. Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. J Exp Clin Cancer Res 2001; 20:117-29. (Pubitemid 32423982)
69. Guindi M. Role of activated host T cells in the promotion of MALT lymphoma growth. Semin Cancer Biol 2000;10:341-4.
70. Ansell SM, Stenson M, Habermann TM, et al. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001;19:720-6. (Pubitemid 32119086)
71. Guidoboni M, Doglioni C, Laurino L, et al. Activation of infiltrating cytotoxic T lymphocytes and lymphoma cell apoptotic rates in gastric MALT lymphomas. Differences between high-grade and low-grade cases. Am J Pathol 1999;155:823-9. (Pubitemid 29426828)
72. Amiot L, Onno M, Lamy T, et al. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br J Haematol 1998;100:655-63. (Pubitemid 28126095)
73. Nocito M, Montalban C, González-Porque P, et al. Increased soluble serum HLA class I antigens in patients with lymphoma. Hum Immunol 1997;58:106-11. (Pubitemid 28093581)
74. Cabrera T, Ruiz-Cabbelo F, Garrido F. Biological implications of HLA-DR expression in tumors. Scand J Immunol 1995;41:398-406.
75. Greiner A, Qin Y, Knorr C, et al. Autoantigen receptors in extranodal non-Hodgkin B-cell lymphomas. Verh Dtsch Ges Pathol 1996;80:160-8.
76. Meyer-ter-Vehn T, Covacci A, Kist M, et al. Helicobacter pylori activates mitogen-activated protein kinase cascades and induces expression of the proto-oncogenes c-fos and c-jun. J Biol Chem 2000;275: 16064-72. (Pubitemid 30366914)
77. Yoshino T, Akagi T. Gastric low-grade mucosa-associated lymphoid tissue lymphomas: their histogenesis and high-grade transformation. Pathol Int 1998;48:323-31. (Pubitemid 28355155)
78. Wöhrer S, Streubel B, Bartsch R, et al. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res 2004;10:7179-81. (Pubitemid 39487703)
79. Rohatiner A, D'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994;5:397-400. (Pubitemid 24159642)
80. Ruskoné-Fourmestraux A, Dragosics B, Morgner A, et al. Paris staging system for primary gastrointestinal lymphomas. Gut 2003;52:912-3. (Pubitemid 36613505)
81. Andriani A, Miedico A, Tedeschi L, et al. Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicentre study. Dig Liver Dis 2009;41:467-73.
82. McLaughlin P, Seymour J, Fuller L, et al. Combined modality therapy for stage I-II MALT lymphoma and mantle cell lymphoma. Ann Oncol 1996;7:211-3. (Pubitemid 26094889)
83. Fischbach W, Dragosics B, Kolve-Gobeler ME, et al. Primary gastric B-cell-lymphoma: results of a prospective multicenter study. Gastro enterology 2000;119:1191-202.
84. Nakamura S, Matumoto T, Suekane H, et al. Predictive value of endoscopic ultrasonography for regression of gastric low-grade and high-grade MALT lymphomas after eradication of Helicobacter pylori. Gut 2001;48:454-60. (Pubitemid 32234787)
85. Caletti G, Zinzani PL, Fusaroli P, et al. The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma. Aliment Pharmacol Ther 2002;16:1715-22.